Tag: Mabwell
-
Mabwell Adalimumab Biosimilar Approved in Indonesia
Indonesia Grants Marketing Approval for Mabwell’s Adalimumab Biosimilar In a move that could broaden access to biologic therapies for autoimmune conditions, Mabwell, a Shanghai-based biopharmaceutical company, announced that its Adalimumab Injection 9MW0113 (marketed as JUNMAIKANG in China) has received marketing approval in Indonesia. The approval marks a key milestone for Mabwell’s global expansion strategy and…
-
Mabwell Adalimumab Biosimilar Approved in Indonesia, Expands Southeast Asia Reach
Overview: Mabwell’s Adalimumab Biosimilar Gains Indonesian Marketing Approval Mabwell, a Shanghai-based biopharmaceutical company renowned for its integrated development-to-manufacturing approach, has secured marketing approval in Indonesia for its Adalimumab Injection 9MW0113, marketed as JUNMAIKANG in China. The green light from Indonesian regulators marks a significant milestone for Mabwell’s global expansion and for patients in Southeast Asia…